PREDNISOLONE SODIUM PHOSPHATE solution Spojené státy - angličtina - NLM (National Library of Medicine)

prednisolone sodium phosphate solution

a-s medication solutions - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone sodium phosphate oral solution is indicated in the following conditions: - allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. - dermatologic diseases: pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. - edematous states: to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. - endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocort

PREDNISOLONE SODIUM PHOSPHATE solution Spojené státy - angličtina - NLM (National Library of Medicine)

prednisolone sodium phosphate solution

carilion materials management - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 15 mg in 5 ml - prednisolone sodium phosphate oral solution (15 mg prednisolone per 5 ml) is indicated in the following conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital ad

PREDNISOLONE SODIUM PHOSPHATE solution Spojené státy - angličtina - NLM (National Library of Medicine)

prednisolone sodium phosphate solution

burke therapeutics - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone sodium phosphate oral solution (20 mg prednisolone base per 5 ml) is indicated in the following conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenit

Betnesol 0.1% w/v Eye, Ear and Nasal Drops, solution Irsko - angličtina - HPRA (Health Products Regulatory Authority)

betnesol 0.1% w/v eye, ear and nasal drops, solution

rph pharmaceuticals ab - betamethasone sodium phosphate - ear/eye/nasal drops, solution - 0.1 percent weight/volume - corticosteroids; betamethasone

Betnesol 500 microgram Soluble Tablets Irsko - angličtina - HPRA (Health Products Regulatory Authority)

betnesol 500 microgram soluble tablets

rph pharmaceuticals ab - betamethasone sodium phosphate - soluble tablet - 500 microgram(s) - glucocorticoids; betamethasone

Diprophos Disposable Syringe 5 mg/ml - 2 mg/ml inj. susp. i.m./i.laes./i.artic./p.artic./i.burs. pre-filled syr. Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

diprophos disposable syringe 5 mg/ml - 2 mg/ml inj. susp. i.m./i.laes./i.artic./p.artic./i.burs. pre-filled syr.

organon belgium bv-srl - betamethasone sodium phosphate 2,63 mg/ml - eq. betamethasone 2 mg/ml; betamethasone dipropionate 6,43 mg/ml - eq. betamethasone 5 mg/ml - suspension for injection - 5 mg/ml - 2 mg/ml - betamethasone sodium phosphate 2.63 mg/ml; betamethasone dipropionate 6.43 mg/ml - betamethasone

Diprophos Disposable Syringe 10 mg/2 ml - 4 mg/2 ml inj. susp. p.artic./i.laes./i.artic./i.burs./i.m. pre-filled syr. Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

diprophos disposable syringe 10 mg/2 ml - 4 mg/2 ml inj. susp. p.artic./i.laes./i.artic./i.burs./i.m. pre-filled syr.

organon belgium bv-srl - betamethasone sodium phosphate 2,63 mg/ml - eq. betamethasone 2 mg/ml; betamethasone dipropionate 6,43 mg/ml - eq. betamethasone 5 mg/ml - suspension for injection - 5 mg/ml - 2 mg/ml - betamethasone sodium phosphate 2.63 mg/ml; betamethasone dipropionate 6.43 mg/ml - betamethasone

Celestone 4 mg/ml inj. sol. i.v./i.m./i.artic./i.laes./i.burs. amp. Belgie - angličtina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

celestone 4 mg/ml inj. sol. i.v./i.m./i.artic./i.laes./i.burs. amp.

organon belgium bv-srl - betamethasone sodium phosphate 5,3 mg - eq. betamethasone 4 mg/ml - solution for injection - 4 mg/ml - betamethasone sodium phosphate 5.3 mg - betamethasone

LAEOVATE N DROPS Ear/Eye Drops, Solution Keňa - angličtina - Pharmacy and Poisons Board

laeovate n drops ear/eye drops, solution

laboratory & allied ltd p.o box 42875 gpo 00100 nairobi, kenya - betamethasone sodium phosphate neomycin sulphate… - ear/eye drops, solution - betamethasone sodium phosphate bp 0.1 % w/v … - otological anti-infectives

BETAMETHASONE VALERATE cream BETAMETHASONE VALERATE ointment Spojené státy - angličtina - NLM (National Library of Medicine)

betamethasone valerate cream betamethasone valerate ointment

cosette pharmaceuticals, inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1.2 mg in 1 g - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hpa axis suppression and cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. hypothalamic-pituitary-adrenal (hpa) axis suppression, cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. administration of topic